Jiangsu Hengrui Medicine (SHA: 600276), a leading pharmaceutical company in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its drug candidate HRS7415 in combination with HRS-8080 for the treatment of breast cancer.
HRS7415 is an anti-tumor agent that works by inhibiting AKT, which affects substrate protein phosphorylation, regulates downstream signaling pathways, and thereby inhibits cell proliferation. The research and development of this drug has cost the company RMB 54.82 million.
HRS-8080 is a selective oral estrogen receptor (ER) degrading agent intended for the treatment of ER positive and ER mutant breast cancer. The development of this drug has cost Hengrui RMB 716.7 million. Both drugs are unique, with no similar products currently approved for marketing worldwide.- Flcube.com
